Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-Blind, Placebo-Controlled, Single-Dose Crossover Study Examining the Effects of Sublingual Riluzole (BHV-0223) on Public Speaking in Social Anxiety Disorder

NCT03017508 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT03017508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03017508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-Blind, Placebo-Controlled, Single-Dose Crossover Study Examining the Effects of Sublingual Riluzole (BHV-0223) on Public Speaking in Social Anxiety Disorder
Lead sponsor
Yale University
Phase
Phase 2/3
Overall status
Completed
Start date
January 31, 2017
Completion date
January 29, 2021
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

performance anxiety, social anxiety disorder